A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression D Engelmann, C Meier, V Alla and BM Pützer p73 is the older sibling of p53 and mimics most of its tumor-suppressor functions. Through alternative promoter usage and splicing, the TP73 gene generates more than two dozen isoforms of which N-terminal truncated DNp73 variants have a decisive role in cancer pathogenesis as they outweigh the positive effects of full-length TAp73 and p53 in acting as a barrier to tumor development. Beyond the prevailing view that DNp73 predominantly counteract cell cycle arrest and apoptosis, latest progress indicates that these isoforms acquire novel functions in epithelial-to-mesenchymal transition, metastasis and therapy resistance. New insight into the mechanisms underlying this behavior reinforced the expectation that DNp73 variants contribute to aggressive cellular traits through both loss of wild-type tumor-suppressor activity and gain-of-function, suggesting an equally important role in cancer progression as mutant p53. In this review, we describe the novel properties of DNp73 in the invasion metastasis cascade and outline the comprehensive p73 regulatome with an emphasis on molecular processes putting TAp73 out of action in advanced tumors. These intriguing insights provoke a new understanding of the acquisition of aggressive traits by cancer cells and may help to set novel therapies for a broad range of metastatic tumors.
INTRODUCTION
The crucial role of the tumor suppressor p73 in cancer has been an area of intense debate. Although the TP53 gene is mutated in 450% of malignant tumors, the impact of TP73 on tumorigenesis depends on a complex pattern of pro-and anti-apoptotic isoforms. Alternative promoter utilization and differential splicing enables TP73 to expand transcript variety and differentially regulate gene expression. In general, TP73 isoforms can be placed into two categories: Transactivating (TA) variants transcribed from the P1 promoter that largely mimic p53 function, and N-terminal truncated variants, termed DNp73, lacking the TA domain, which counteract the tumor-suppressor activity of p53 and p73. Most of these truncated forms originate from differential splicing events at the 5′-end of P1-derived transcripts (ΔEx2p73, ΔEx2/3p73, ΔN′p73; called ΔTA), while ΔN arises from the alternative P2 promoter within intron 3. 1 The 3′-end of the TP73 gene transcript is considered as transcriptional-negative regulator containing an additional TA domain, a sterile alpha motif involved in protein-protein interaction, and a transcriptional inhibitory domain. Splicing at the carboxyterminus generates again multiple isoforms that differ in their transactivation efficiency and target gene specificity. Based on the presence of the TA domain, wild-type p73 and C-terminal variants exhibit transcriptional activities regulating cell proliferation, differentiation, apoptosis, autophagy or metabolism. Conversely, DNp73 acts as dominant-negative inhibitor of p53 and TAp73 by competing for DNA through p53-responsive elements or by formation of inactive oligomers. The antagonistic variants confer drug resistance to cancer cells harboring wild-type p53/p73 proteins by opposing their growth-suppressive and cell deathinducing properties. In addition, there is also compelling evidence that DNp73 isoforms show their own distinct activities independent of any p53/TAp73 antagonism and endow cells with gain-offunction (GOF). [2] [3] [4] Both TAp73 and DNp73 are abundantly expressed in a variety of human cancers, including bladder, breast, colon, lung, ovarian and hepatocellular carcinoma, neuroblastoma and malignant melanoma, and this upregulation correlates with poor prognosis. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Although the tumorsuppressor function of TAp73 has long been recognized, the contribution of tumor-associated TAp73, DNp73 and their ratio in molecular cancer pathogenesis remains hitherto elusive. Given their elevated expression especially in a broad range of advanced tumor stages and metastases, [18] [19] [20] [21] the role of amino-truncated variants extends well beyond the previously recorded transforming activity in normal cells. On the other side, TAp73 appears in its original apoptosis-mediating function decoupled, which enables cancer cells to tolerate high levels of TAp73 while entering the surrounding tissue. This review highlights the latest and most exciting discoveries in the field summarizing the cell-context dependent tumor-suppressor activities of TAp73 and progress in the assessment of mechanisms underlying the aggressive traits of DNp73 in cancers with disconnected TAp73. This new understanding of the signaling pathways and regulatory network involved unlocks great potential for the development of future anti-metastatic therapies.
CANCER-FIGHTING PROPERTIES OF TAP73
Growth arrest and genome maintenance Inhibition of cell-cycle progression, maintenance of genome stability and promotion of apoptotic cell death are the key mechanisms by which TAp73 contributes to tumor surveillance, causes cytotoxicity and eliminates cancer cells in response to DNA-damaging anti-cancer drugs. As a member of the p53 family, TAp73 can induce these effects by activating p53-responsive genes as well as p53-independent pathways. TAp73 mediates cell cycle arrest in G1 and G2/M through transcriptional activation of the p53 targets p21 or GADD45. 22, 23 Moreover, TAp73 limits number of division cycles via indirect regulation of human telomerase reverse transcriptase (hTERT) expression. TAp73 forms a complex with Sp1 and thereby prevents Sp1 binding to the corresponding sites in the hTERT promoter. 24, 25 TAp73 knockout mice show enhanced genomic instability and high incidence of spontaneous tumors. 26 Mismatch repair proteins contribute to genome integrity by correcting replication errors. Upon accumulating DNA damage, the mismatch repair protein PMS2 binds and stabilizes TAp73. 27 This interaction allows redistribution of PMS2 to the nucleus. TAp73 itself is also a transcriptional regulator of base excision repair genes, such as the glycosylases SMUG1 and MUTYH. 28 Consequently, TAp73 downregulation results in increased DNA damage. TAp73 is essential for cells to cope with DNA double-strand breaks as evident from mouse models, as it is required for Mre11, RAD51 and BRCA2 upregulation. 29 Key components of the Spindle Assembly Checkpoint Bub1, Bub3 and BubR1 interact with TAp73, which is required to maintain proper mitotic arrest. 30 In addition, TAp73 is phosphorylated in a cell cycle-dependent manner and regulates p57 transcription to coordinate mitotic exit. 31 TAp73 induces mitotic cell death via direct BIM transactivation 32 and suppresses polyploidy and aneuploidy independently of p53. 33 These observations define a central role of this tumor suppressor as a guardian of genome integrity (Figure 1a ). 34, 35 Apoptosis and autophagy TAp73 accumulates upon genotoxic or oncogenic stress and triggers cell death through a plethora of pathways and mechanisms. It directly promotes mitochondria-mediated apoptosis by activating p53 target genes such as BCL-2 family members BAX, PUMA, NOXA, BAD, BIK and the mitochondrial membrane protein p53AIP1. 36 PUMA, which triggers Bax mitochondrial translocation and release of cytochrome c, subsequently activates the intrinsic caspase cascade leading to mitochondria-mediated apoptosis. 37 Moreover, p73 elicits p53-independent mitochondrial apoptosis through direct transcriptional activation of GRAMD4 (alias KIAA0767 or Death-Inducing-Protein). 38 GRAMD4 translocates to the mitochondria, physically interacts with Bcl-2, promotes Bax mitochondrial relocalization and oligomerization and is highly efficient in inducing mitochondrial membrane permeabilization with release of cytochrome c and Smac. Additionally, consistent with a direct role of p53 at the mitochondria, 39 the full-length protein and some of its products cleaved by caspases in response to DNA-damaging agents and death-receptor activation were found at the mitochondria, supporting that p73 also has a transcription-independent function in the progression of apoptosis. 40 Recent findings indicated that RanBP9 cooperates with p73 to induce mitochondrial apoptosis. RanBP9 stabilizes p73 at the transcriptional and posttranslational level via physical interaction. 41 Furthermore, the ability to stimulate expression of the death receptors CD95, tumor necrosis factor (TNF)-R1, TRAIL-R1 and TRAIL-R2 as well as the caspases-3, -6 and -8 suggests that p73 is also involved in the extrinsic apoptosis pathway. 10, 12 Induction of p73-dependent programmed cell death following DNA damage also involves endoplasmic reticulum stress and upregulation of scotin, a putative transmembrane protein able to colocalize with endoplasmic reticulum heat-shock proteins, such as GRP94. 42 It was shown that NIS/SLC5A5, a transmembrane glycoprotein that mediates active iodide uptake into thyroid follicular cells, is stimulated after doxorubicin treatment of liver cancer cells in a TAp73-dependent manner. 43 Knockdown experiments revealed that upregulation of NIS contributes to DNA-damage-induced apoptosis by yet undetermined mechanism(s).
Other mechanisms by which TAp73 induces cell death encompass inhibition of anti-apoptotic or activation of proapoptotic signaling cascades. TAp73 upregulates the transcriptional co-repressor promyelocytic leukemia (PML), which in turn binds the promoter of epidermal growth factor receptor and prevents its transcription, leading to apoptosis induction in cancer cells addicted to this oncogenic RTK. 44 In addition, p73 upregulates IGFBP3, which is a potent inducer of cancer cell death and endogenous chemosensitizer through insulin-like growth factor 1 receptor (IGF1R) signaling-dependent and -independent mechanisms. 45, 46 The c-Jun N-terminal kinase (JNK) signaling pathway responses to various stress stimuli and, intriguingly, its activation depends on TAp73 activity. 47 The underlying mechanism involves induction of the TAp73 target GADD45 that subsequently activates the JNK pathway via MTK1/MEKK4. Interleukin 4 receptor (IL4R) is activated by TAp73 in response to chemotherapy, and TAp73-overexpressing cancer cell lines are sensitive to IL4-mediated cell death. 48 It was shown that pigment epithelium-derived factor (PEDF), a secreted 50-kDa glycoprotein capable of inducing pro-apoptotic signaling cascades, 49 is a direct target gene of TAp73. 50 This raises the question whether TAp73 is able to induce apoptosis in a paracrine or autocrine manner involving the PEDF receptor PNPLA2, 51 as an inverse correlation between inhibitory p73 isoforms and PEDF has been observed. 52 Furthermore, TAp73 is also an integral component of other death-inducing signaling cascades, such as transforming growth factor (TGF)-β or TNF-α. 53, 54 Autophagy is a membrane trafficking process that in response to stress promotes the lysosome-dependent degradation of proteins and organelles. It has both tumor suppressive and oncogenic capacities depending on cellular contexts. However, mice with defects in the molecular machinery of autophagy have an increased frequency of tumor development. 55 Although exact mechanisms by which autophagy induces apoptosis still remain elusive, the protein damage-regulated autophagy modulator (DRAM) is critical for autophagic cell death. TAp73 induces autophagy and transcription of DRAM, but according to the study of Crighton et al. 56 p73-induced autophagy is DRAM independent and does not contribute to cell death. A recent report demonstrates that ASPP2, a p73 interacting partner, activates the p73-DRAM pathway as well as the transcription factor CHOP (C/EBP homologous protein) that mediates Beclin-1 release required for autophagy. 57 In their model, p73-mediated DRAM expression and CHOP-released Beclin-1 act in concert to induce autophagic cell death. The nutrient-sensing kinase mammalian target of rapamycin (mTOR) suppresses TAp73. Treatment with the mTOR-inhibitor rapamycin leads to transcription of TAp73-dependent genes associated with starvation-induced autophagy. 58 Another study shows that TAp73 regulates autophagy through direct transactivation of the promoter of autophagyrelated protein 5 (ATG5), which is required for the formation of autophagosomes. 59 Compared with wild-type mice, mice functionally deficient in all p73 isoforms exhibit decreased ATG5 expression and lower levels of autophagy. In an approach to efficiently destruct therapy-resistant metastatic melanoma cells, lifting epigenetic blockage and re-expression of TAp73 by oncolytic viruses caused enhanced cytotoxicity as a result of apoptosis and autophagy induction. 60 This suggests that p73-mediated autophagy compensates for p53 inactivation and has promising therapeutic potential.
Redox maintenance and metabolism Increased oxidative damage caused by defects in scavenging systems and accumulation of reactive oxygen species (ROS) predisposes to cancer. TAp73 regulates mitochondrial respiration by directly transactivating COX4I1, an essential component of the mitochondrial complex IV, and thereby prevents ROS accumulation. 61 Ablation of TAp73 increases oxidative stress that could drive oncogenic mutations jointly with previously observed genomic instability. 26 In addition, TAp73 provides a fail-safe mechanism by inducing ATM (ataxia telangiectasia mutated)triggered apoptosis in response to persistent accumulation of ROS. 62 Cancer cells reprogram their energy metabolism by predominantly utilizing cytosolic aerobic glycolysis and lactate fermentation rather than mitochondrial oxidative phosphorylation of pyruvate for their energy production to promote rapid cell proliferation. 63 In this regard, TAp73 knockout cells exhibit decreased ATP levels and increased glucose addiction, indicating a switch in energy metabolism. 61 However, an unexpected and paradigm shifting aspect of TAp73 has emerged through recent studies showing that TAp73 is linked to oncogenic cell growth. G6PD, the rate-limiting enzyme in the pentose phosphate pathway, is a transcriptional target of TAp73. TAp73-induced G6PD increases pentose phosphate pathway flux and directs glucose to the production of NADH and ribose, which is essential for macromolecule synthesis and scavenging of ROS. 64 Depletion of TAp73 impairs proliferation but can be rescued by G6PD reexpression or the presence of nucleosides and ROS scavenger. In this context of cancer cell metabolism, others showed that TAp73 promotes GLS2 transcription and thus drives serine biosynthesis. 65 Serine is a precursor for other amino acids, glutathione, lipids and nucleotides essential for cancer cell survival. Importantly, TAp73 ablation interferes with cell proliferation, indicating that aberrant TAp73 activity is essential for cancer cells to cope with metabolic/ oxidative stress. Of course, these results are in conflict with the tumor-suppressor role of TAp73 but suggest that high levels of transcriptionally competent TA isoforms in malignant cells 66 rather reflect a GOF than a simple counter regulation in response to increased DNp73 expression. In support of this assumption, G6PD is solely responsive to TAp73 isoforms. 64 Thus tumor cells might benefit from TAp73 upregulation even in the presence of abundant DNp73 or mutant p53. However, this model requires that the original tumor-suppressor function of TAp73 is lost, which could be achieved by its interplay with inhibitory DNp73 isoforms, cofactors or upstream regulators.
N-TRUNCATED DNP73 VARIANTS IN CANCER PROGRESSION
The oncogenic capacity of DNp73 isoforms was initially demonstrated in fibroblasts by overexpression of ΔEx2/3p73 or ΔNp73 leading to malignant cell transformation and tumorigenicity in nude mice either alone or in cooperation with RAS, MYC and E1A. 67, 68 Whereas downregulation of TAp73 is a key transforming activity of oncogenic Ras mutants independent of p53, TAp73 has been shown to suppress malignant transformation by limiting anchorage-independent growth via upregulation of the cell surface protein KCNK1. 69 DNp73 transgenic mice display aberrant cell growth of hepatocytes and develop hepatic carcinomas. 70 In addition, DNp73 blocks terminal differentiation and thus prevents tissue maturation. 71, 72 Mechanistically, DNp73 isoforms inactivate TP53 and TAp73 proteins by competing for binding sites as DNtetramers or forming heterocomplexes lacking transcriptional activity. [73] [74] [75] [76] [77] Moreover, DNp73 blocks the tumor-suppressor function of retinoblastoma by triggering its hyperphosphorylation, which results in enhanced E2F release through activation of cyclin E-cyclin-dependent kinase 2 (Cdk2) and cyclin D-Cdk4/6 kinases, Figure 1 . Cellular processes regulated by TA and DNp73 isoforms determining cancer outcome. (a) Upon cellular stress, TAp73 expression and activity increases to stimulate or repress transcription of target genes involved in a wide range of biological processes suppressing tumor growth and development, for example, growth arrest, apoptosis induction, autophagy, genome maintenance and anchorage-independent growth. In addition, TAp73 has also transcription-independent activities involving protein interaction with components of the spindle assembly complex to maintain proper mitotic arrest and with RanBP9 to release cytochrome c. Unexpectedly, TAp73 increases biosynthesis of macromolecules implying a role in metabolic reprogramming in advanced cancer with high TAp73 levels. (b) Amino-terminal truncated DNp73 variants drive tumor progression and confer chemoresistance, stemness and invasiveness through inhibition, de-repression or activation of target genes. Importantly, upregulation of DNp73 induces EMT, a key process during the invasion metastasis cascade.
p73 variants in cancer progression D Engelmann et al and downregulation of cell cycle inhibitors p21 and p57. 70, 71, 78 This tumor-promoting effect of DNp73 is independent from its inhibitory activity on wild-type p53 family proteins and represents a GOF. Apart from interfering with classical tumor-suppressor pathways, DNp73 isoforms exert their oncogenic activity through a plethora of novel pathways and mechanisms and thereof have a crucial impact on clinical behavior of aggressive tumors (Figure 1b ).
Chemoresistance
DNp73 expression levels correlate with dampened apoptotic response to therapy and increased cell death resistance in many cancers. Upregulation of both TAp73 and DNp73 in cervical squamous cell carcinomas significantly correlates with the sensitivity to radiotherapy and patient's survival in a different prognostic manner. An increase of DNp73 is mainly detected in tumors resistant to irradiation, whereas high TAp73 expression is associated with radiosensitivity and predicts better survival. 79, 80 DNp73 is an important determinant for failure of platinum-based chemotherapy in p53-mutant ovarian cancers. 81 In addition, patients with hepatocellular carcinomas overexpressing DNp73 had a significantly shorter survival time compared with patients whose tumors were DNp73 negative. 12 These data suggest that an unbalanced ratio of DNp73 and TAp73 might render cancer cells more responsive to radiotherapy or chemotherapy. By blocking TAp73 transactivation activity on target gene promoters, DNp73 suppresses death-receptor signaling and apoptosis emanating from mitochondria making tumors more resistant to DNAdamaging drugs. 82, 83 Besides attenuating TAp73-dependent apoptosis, DNp73 confers multidrug resistance by increasing the expression of ABCB1/MDR1 through association with p53 at the promoter level. 84 In addition, our lab uncovered an indirect mechanism by which other ATP-binding cassette (ABC) transporter family members are regulated. ΔEx2/3p73 interferes with TAp73-mediated activation of miR-205 transcription in cisplatintreated melanoma cells. As a consequence, miR-205-dependent repression of ABCA2, ABCA5 and Bcl-2 is abolished that will foster anti-cancer drug resistance. 85, 86 In addition to the ability of DNp73 variants to compete for DNA binding with TA isoforms of the p53 family, several lines of evidence indicate that also transcriptionalindependent mechanisms account for evasion from chemotherapy. ΔNp73 -/cells are sensitized to genotoxic agents due to an elevated DNA-damage response that triggers apoptosis. 87 This study revealed an interaction between the sensor protein 53BP1 and DNp73 at the sites of DNA damage, which inhibits signal transduction. This prevents ATM activation and subsequent p53 stabilization through phosphorylation. Moreover, ΔNp73 binds and inhibits JNK, which protects cells from apoptosis. 88 Transcriptional downregulation of the tumor-suppressor phosphatase and tensin homolog (PTEN) by DNp73 leads to reduced apoptosis and increased cancer cell proliferation. 89 Epithelial-to-mesenchymal transition (EMT), cell invasion and stemness EMT is a highly conserved developmental process whose aberrant activation in cancer cells is associated with tumor progression and metastasis. The phenotypic conversion during EMT includes loss of cell-cell junctions, loss of apico-basal polarity and acquisition of migratory and invasive properties, including the ability to degrade the extracellular matrix. Typically, these phenotypic changes are associated with loss of epithelial markers such as E-cadherin and upregulation of mesenchymal proteins such as N-cadherin, vimentin or fibronectin. In this regard, several recent studies define the DNp73 isoforms as novel regulators of EMT during malignant progression in cancer.
DNp73 is aberrantly expressed in advanced stages of different cancers, for example in metastases of skin cancer patients, 15 suggesting a more complex role of these isoforms in cancer pathogenesis with further activities beyond transforming cells to tumorigenicity. Knockdown of endogenous DNp73 in highly metastatic melanoma cell lines using an isoform-specific antisense-oligonucleotide abolished the aggressive phenotype, whereas tumor xenografts overexpressing this variant possess significantly greater capacity to invade the surrounding tissue and form metastatic lesions. 20 Importantly, proliferation of tumor cells with increased DNp73 is not affected, demonstrating that this oncogene exhibits, in contrast to its function in untransformed cells, an independent ability to drive invasion. DNp73 induces a mesenchymal phenotype accompanied by a drastic reorganization of the cytoskeleton, loss of E-cadherin and upregulation of N-cadherin as well as vimentin. During EMT loss of E-cadherin is often a result of transcriptional silencing mediated by the EMT transcription factors Twist, Zeb, Snail or Slug. We showed that DNp73 facilitates EMT by triggering upregulation of Slug. The underlying mechanism involves direct interference with TAp73dependent transcription of the tumor-suppressor LIMA1/EPLIN. EPLIN is located along actin stress fibers and focal adhesion plaques where it has a role in maintaining cell morphology and tissue integrity. Consistent with this idea, high DNp73 expression is inversely correlated with low levels of EPLIN at the invasive front of primary melanoma from patients as cells break into the underlying dermis. As a consequence of DNp73-mediated EPLIN repression, the IGF1R-AKT/STAT3 (signal transducer and activator of transcription factor 3) signaling axis becomes activated fostering an increase of Slug and consecutive attenuation of E-cadherin expression. 20 Additionally, studies in colon cancer cells revealed that TAp73 also directly represses IGF1R gene expression, 90 suggesting an expanding role of p73 isoforms in regulating IGF1R activation and expression. In light of these findings, it is reasonable to assume that the ratio between TAp73 and DNp73 determines a molecular switch to initiate EMT. Intriguingly, association of IGF1R signaling with the development of resistance to BRAF inhibitors has been reported, 91 linking DNp73-dependent activation of EMT programs with enhanced drug resistance in highly malignant tumor cells.
Mammary epithelial cells form polarized spheroids called acini, and disruption of normal acinar architecture is a hallmark of breast cancer progression. Three-dimensional culture of MCF10A cells leads to formation of acinar structures that remarkably mimic normal acini in vivo. Interestingly, isoform-specific depletion of TAp73 in this model (leaving DNp73 expression unaltered) induces loss of apico-basal polarity accompanied by E-cadherin ablation, nuclear accumulation of β-catenin and increased expression of laminin V, Snail, Slug and Twist. 92 Further investigations revealed that loss of TAp73 in these untransformed cells causes downregulation of the EMT inhibitors p21 and PUMA leading to a DNp73-dependent upregulation of EMT transcription factors. 93 EMT can be triggered by many extracellular signals such as TGF-β being one of the most potent inducers. However, TGF-β signaling has both tumor suppressing and promoting activities. The diverse response of this pathway to essentially the same input signal depends on cooperation with factors that are expressed in a cell context-dependent manner. Activation of TGF-β receptors leads to translocation of Smads into the nucleus. Per se, Smads exhibit low affinity to DNA and therefore require additional transcription factors to activate TGF-β target genes. In this context, DNp73 forms a complex with TGF-β-induced nuclear Smads and directly interacts with DNA Smad-binding elements. 2 This interaction results in a synergistic upregulation of PAI-1 and COL1A1 and represents a DNp73-dependent GOF regardless of p53responsive elements that confers increased metastatic potential to TGF-β-stimulated cells. It is likely that DNp73 isoforms regulate EMT also by other, yet undefined, mechanisms, such as activation of the adhesion molecule periostin. 94 p73 variants in cancer progression D Engelmann et al PDGFRB (platelet-derived growth factor receptor, beta polypeptide) is overexpressed in many cancers, and autonomous PDGFRB signaling drives metastasis. 3 TAp73 hampers PDGFRB transcription through direct association with the transcription factor NF-Y, and this interaction is enhanced by DNA damage. The inhibitory TAp73/NF-Y complex is disrupted by both DNp73 and mutant p53 proteins, suggesting that accumulation of N-truncated p73 isoforms takes the role of mutant p53 as a GOF in p53-deficient cancers (Figure 2 ). 3, 4, 77, 95 Emerging evidence suggests a phenotypic association between cancer cells undergoing EMT accompanied with increased drug resistance and the acquisition of cancer stem cell-like phenotype. 96 NANOG is a key embryonic stem cell transcription factor and acts as inducer of pluripotency in mammalian cells. DNp73 dramatically enhances reprogramming of human fibroblasts into induced pluripotent stem cells by directly stimulating the expression of NANOG. 97 In addition, induced pluripotent stem cells with ectopic DNp73 have higher levels of other stem cell transcription factors such as cMyc, KLF4 and OCT4 and generate less differentiated teratomas in vivo. These data in conjunction with the recently uncovered role of IGF1R signaling for preserving cancer stem cell traits 98 point out that amino-truncated p73 is a putative mediator of stem cell transformation and potentially involved in cancer stem cell generation. This will certainly be an area of further research.
THE P73 REGULATOME
Within the p53 family, the TP73 gene generates the largest number of isoforms, including N-and C-terminal variants. TAp73 and DNp73 variants have opposing roles as well as unique functions independent of any dominant-negative antagonism. Expression and activity of the TP73 products is tightly controlled by multiple molecular mechanisms. They are key to understand how the cellular functions of this gene are orchestrated and become deregulated during tumor progression. A very recent study indicates that, despite its greater sequence homology to TAp63, TAp73 does not exhibit an autoinhibited state in 'healthy cells' but rather can readily form active tetramers. However, TAp73 is addicted to covalent modifications and transcriptional coregulators for full transactivation potential. 99 Over the past decade, identification of transcription and splicing factors, binding partners, signaling pathways and enzymes that regulate gene expression, posttranslational modifications, protein turnover and transcription of p73 target genes and its isoforms has become an extensive area of research. 19, 35 A comprehensive regulatory network has been unraveled that modulates the ratio and activity of the different p73 isoforms and determines the differential response to p73-induced target genes (Figure 3 ).
PRO TAP73-CONTRA DNP73 ACTIVITY Steering TAp73 activity via stability control
Under normal cellular conditions TAp73 is in complex with the E3 ubiquitin ligase ITCH promoting proteasomal degradation. Upon DNA damage, ITCH expression is downregulated allowing TAp73 to accumulate. 100 The proteins N4BP1 and TAp73 share the same binding site for ITCH. Thus, by competing with TAp73 for ITCH binding, N4BP1 reduces the ability of ITCH to recruit and ubiquitinate TAp73. 101 The U-box-type E3/E4 ubiquitin ligase UFD2a promotes the proteasomal turnover of p73, however, in a ubiquitination-independent manner and is downregulated in response to cisplatin-induced apoptosis. 102 Another crucial regulator of TAp73 ubiquitination-independent degradation pathways is NQO1 that functions as a gatekeeper of the 20S proteasomes. Following irradiation, it physically interacts with TAp73 in an NADH-dependent manner and protects from 20S proteasomal degradation. 103 Another key regulator of p73 stability is histone deacetylase 1 (HDAC1). HDAC1 is required for TAp73 accumulation after DNA damage, as it triggers interaction between Hsp90 and TAp73. Depletion of HDAC1 results in hyperacetylation of Hsp90 and disruption of the complex with TAp73 that becomes degraded subsequently. 104 Regulation of TAp73 mRNA stability is a recently uncovered mechanism by which TAp73 accumulation is achieved. The RNA-binding protein RNPC1 interacts with a CU-rich element in the 3′-untranslated region of TAp73 and prevents mRNA decay. 105 Because of direct transcriptional regulation of RNPC1 by TAp73, they constitute a novel feed-forward loop amplifying the DNA-damage response in p53-deficient tumors.
The transcriptional core complex c-Abl-YAP1-PML-TAp73 mediates apoptosis In the absence of genotoxic stress, the transcriptional activity of TAp73 is blocked during the cell cycle through phosphorylation by cyclin A-CDK1/2, cyclin B-CDK1/2 and cyclin E-CDK2 complexes. 106 YAP1 is the key transcriptional co-activator of TAp73-dependent transcription of pro-apoptotic genes in the presence of chemo- p73 variants in cancer progression D Engelmann et al therapeutic drugs and, in addition, protects p73 from degradation through competing with ITCH for sterile alpha motif domain binding. 107 In damaged cells, the TAp73-YAP1 complex is recruited to PML nuclear bodies, 108 which are macromolecular multiprotein complexes centered around the transcription factor and tumor-suppressor PML and regulate genes required for cell death, senescence and differentiation. At the same time, the PML gene is also a transcriptional target of TAp73-YAP1. PML directly binds and stabilizes YAP1 through SUMOylation as part of a positive feedback loop that enhances TAp73-dependent transcription. 109 The formation of the TAp73-YAP1 complex is induced by the non-receptor tyrosine kinase c-Abl. Under physiological conditions c-Abl is restrained in the cytoplasm via interaction with 14-3-3ζ, which becomes phosphorylated by JNK when cells are exposed to genotoxic agents. 110 Consequently, c-Abl translocates to the nucleus, is activated by ATM 111, 112 and phosphorylates both TAp73 and YAP1 thereby augmenting their interaction. 113, 114 In addition, phosphorylation of YAP1 by c-Abl also disrupts its interaction with the transcription factor RUNX at the ITCH promoter causing transcriptional silencing and further accumulation of TAp73. 115 However, acetylation of TAp73 is required for full transcriptional activity. c-Abl-mediated phosphorylation of TAp73 promotes the interaction with the prolyl isomerase PIN1. 116 PIN1 alters p73 conformation, which allows p300-mediated acetylation. Acetylation of TAp73 by p300 then dictates selective activation of pro-apoptotic genes. 117 c-Abl appears to be a major upstream regulator of TAp73 activity during cell stress and initiates TAp73 phosphorylation also via alternative mechanisms, such as activation of p38 118 or PKCδ, 119 which becomes constitutively active through cleavage by caspase-3, resulting in TAp73 phosphorylation. 120 Activation of TAp73 by c-Abl requires an intact mismatch repair machinery. 121 However, pathways exist which bypass a defective c-Abl-TAp73 axis in cancer cells: Several studies indicate that JNK directly phosphorylates TAp73 in a c-Abl-independent manner and contributes to DNA-damage-induced apoptosis. 122, 123 Co-activators and repressors determine TAp73 anti-tumor activity A large body of evidence indicates that TAp73-mediated gene transcription depends on the interaction with transcriptional cofactors in addition to YAP1. ASPP1 and ASPP2 selectively potentiate DNA binding and transcriptional activity of TAp73 on the promoters of pro-apoptotic genes PUMA, BAX and PIG3 through direct interaction. 124, 125 Some cofactors are also direct TAp73 target genes generating a positive feedback during the response to DNA damage. TAp73-dependent induction of 14-3-3σ mediates chemosensitivity of adriamycin-resistant breast cancer cells by increasing BAX transcription. 126 The tumor-suppressor PTEN is primarily known for the inhibition of the AKT/PKB signaling pathway via its cytoplasmic phosphatase activity but has also nuclear functions. In response to genotoxic drugs, a TAp73/PTEN complex in the nucleus of damaged cells is formed that enhances transcription of BAX and PUMA independently of p53. 127 Although oncogenes such as c-Myc bind TAp73 to inhibit transcriptional activation of target genes such as BAX, the nuclear c-Myc-binding protein MM1 interacts with TAp73 and prevents this interaction. 128 Consequently, increased c-Myc expression in advanced tumor stages could overcome MM1 blockade and attenuate TAp73-induced apoptosis and growth suppression.
Furthermore, an interesting study shows that protein binding partners have an influence on transcriptional-independent activities of TAp73 and sensitize for radiotherapy. In this regard, the expression of TAp73 leads to stabilization of its binding partner BCA3. The data indicate that TAp73-BCA3 complexes translocate from the nucleus to mitochondria and induce the release of cytochrome c with subsequent activation of caspases. 40, 129 Apart from cell death induction, repression of genes relevant for cell migration is a major anti-tumor activity of TAp73 but requires cooperation with co-repressors. The serine/threonine kinase HIPK2 was shown to colocalize with TAp73 at PML nuclear bodies. 108 HIPK2 binds TAp73 and interferes with transcription of collagenase and β 4 -integrin, which impairs tumor progression. In contrast, depletion of HIPK2 upregulates β 4 -transcription promoting AKT phosphorylation, anchorage-independent growth and invasion. 130 Overall, this means that cells which are able to downregulate expression or activity of these proteins could deactivate the tumorsuppressor activity and tolerate increased expression of TAp73. For instance, recent studies have shown that reduced ASPP2 expression frequently occurs in human head and neck squamous cell carcinomas and strongly correlates with metastasis. 131 Moreover, higher ASPP1 promoter methylation is linked to decreased protein levels and malignant tumor progression, 132 implicating abolished transcriptional activity of TAp73 towards pro-apoptotic target genes during cancer progression.
DNA damage suppresses DNp73
The balance between full-length and N-terminally truncated p73 isoforms is critical for cell fate in response to environmental stress. When cells that preserved the tumor-suppressor activity of TAp73 are exposed to DNA damage, several mechanisms selectively favor abundance of the TA isoforms and target DNp73 thereby increasing the TA/DN ratio. The ring finger domain ubiquitin ligase PIR2 is a transcriptional target of DNA-damage-induced TAp73. 133 It binds TA and DN isoforms of p73 but selectively stabilizes TAp73 and degrades DNp73 through ubiquitination. These data indicate that PIR2 regulates TAp73 function through fine-tuning the TA/DN ratio in a positive feedback loop. In addition, genotoxic stress induces members of the AP-1 transcription factor family, which suppress the transactivation of the polyamine catabolic enzyme PAOX. 134 The result is that polyamines are synthesized to induce the expression of antizyme AZ1, which in turn mediates degradation of DNp73. 135 Recently, another degradation-dependent mechanism was identified that differentially regulates TP73 protein isoforms. In the absence of DNA damage, the HECT-type E3 ligase WWP2 preferentially binds TAp73 in a monomeric state and drives its proteasome-dependent degradation. 136 WWP2 interacts with another E3 ligase, WWP1, which specifically binds and destabilizes DNp73. The protein phosphatase PPM1G acts as a functional molecular switch favoring stability of TAp73 by inhibiting catalytic activity of monomeric WWP2 and assembly of the WWP2-WWP1 heterodimeric complex during genotoxic drug treatment. Interestingly cadmium, a carcinogenic heavy metal, is a specific PPM1G inhibitor implying that PPM1G might act as a potential tumor suppressor via regulating TAp73 and DNp73 levels in stress conditions. 137 The dominant-negative ΔNp73 isoform is generated through alternative promoter usage. Qian et al. 138 unraveled a transcriptional mechanism of differential p73 variant regulation. The basic helixloop-helix transcription factor DEC1 is a DNA-damage-inducible target of TAp73. It directly transactivates the P1 but represses the P2 promoter thus shifting the balance towards TAp73. 139 DEC1 recruits HDAC8 solely to the P1 promoter, thereby enhancing transcription of TAp73. Interestingly, downregulation of DEC1 is associated with increased cancer cell migration and tumor progression. 140, 141 CONTRA TAP73-PRO DNP73 ACTIVITY TAp73-induced apoptosis counterattacked: evading DNA damage in cancer A number of survival signaling pathways, destabilizing enzymes and co-repressors dampen TAp73-induced apoptosis, and their deregulation constitutes potential mechanisms of chemotherapy evasion in advanced tumors. The ubiquitin ligase mouse doubleminute 2 homolog (MDM2) is deregulated in many human cancers and exerts its oncogenic activity predominantly by inhibiting p53. However, MDM2 inhibition induces apoptosis in p53-deificent tumors by activating TAp73-dependent apoptosis. 142 In contrast to p53, MDM2 does not directly interact with TAp73 but indirectly promotes protein degradation through interaction with ITCH. 143 FBXO45, a novel ubiquitin ligase, is overexpressed in cancer cells causing TAp73 degradation, whereas ablation of FBXO45 stabilizes the tumor-suppressive form and concomitantly induces cell death in a p53-independent manner. 144 Moreover, covalent modification by SUMO-1 facilitates degradation of TAp73. 145 In contrast to SUMO-1, interaction of PIAS-1 with TAp73 leads to protein stabilization. Paradoxically, PIAS-1-mediated SUMOylation is not required for protein accumulation but diminished the ability of TAp73 to transactivate target genes in order to overcome cell cycle arrest and apoptosis. 146 Following cellular damage, YAP1 is phosphorylated by Akt, binds to 14-3-3 proteins and relocalizes to the cytoplasm, which suppresses induction of TAp73-dependent pro-apoptotic gene expression. 147 Other pro-survival kinases directly target TAp73: Chemotherapy upregulates PLK3 that attenuates apoptosis through phosphorylation of TAp73 leading to decreased protein stability. 148 Similarly, another polo-like kinase family member, PLK1, colocalises to the damaged nuclei of drug-treated cells and phosphorylates TAp73 at the N-terminus promoting proteolytic degradation in a proteasome-independent manner. 149 In contrast to untransformed cells, drug-resistant cancer cells frequently overexpress PLK1 and thereby inhibit TAp73-mediated transactivation. Silencing PLK1 upregulates TAp73 and might be a promising approach for resensitizing drug-resistant cells to conventional chemotherapy. 150 Tumors exploit mechanisms that specifically lead to TAp73 relocalization. Overactivated NEDDylation pathways are implicated in cancer metastasis. 151 TAp73 is covalently modified by NEDD8 in a MDM2-dependent manner and induces translocation of TAp73 from the nucleus to the cytoplasm. 152 As NEDDylation requires binding of MDM2 to the N-terminal TA domain, only TA isoforms are affected by this modification. The kinase Aurora-A is correlated with chemotherapy resistance, and a study revealed elevated cytoplasmic p73 in Aurora-A kinase overexpressing human tumors. 153 Aurora-A phosphorylates TAp73, which subsequently loses its transactivation activity and phospho-TAp73 is tethered to the cytoplasm through interaction with mortalin, a member of the HSP79 family. In line with these notions, DNp73 isoforms are mainly localized in the nucleus, while TAp73 is sequestered in the cytoplasm in lung and pancreas cancer patients. 153, 154 TAp73 also becomes phosphorylated by the Src family kinase HCK. This induces its retention in the cytoplasm and repression of its transcriptional activity, suggesting enhanced resistance against pro-apoptotic drugs in tumors with high HCK activity. 155 High levels of eEF1A1, a GTPase alpha subunit of the elongation factor-1 complex, have been reported in melanomas as well as p73 variants in cancer progression D Engelmann et al breast and lung tumors and correlate with the metastatic potential of cancer cells. Noteworthy, eEF1A1 is a novel interacting partner of TAp73 that inhibits chemotherapy-induced cell death. 156 The mechanism of TAp73 inhibition by eEF1A1 remains elusive but is not due to changes in protein stability. Coming back to aggressive melanoma and their potential resistance to BRAF inhibition, it was recently demonstrated that cells withstanding drug treatment overexpress the deubiquitinase USP5. Knockdown of USP5 recovered TAp73 activity and sensitized BRAF and NRAS mutant melanoma for targeted therapy. 157 Switching the balance in favor of DNp73 Cancer cells compensate the tumor-suppressor function of TAp73 through shifting the ratio or transcriptional activity towards DNp73 isoforms. A number of mechanisms have been unraveled that account for DNp73 accumulation and overactivity. Here, epigenetic regulation of P1 and P2 promoter is another regulatory layer to control differential expression of TA and DN isoforms in cancer cells. P2 hypomethylation-associated overexpression of ΔNp73 mRNA is a frequent event in lung cancer 158 and also observed in neuroblastoma. 159 A very recent paper suggests that promoter methylation in breast cancer cells redirects the transcription factor Nrf-2 from P1 to P2. 160 In non-tumor tissues, Nrf-2 is able to bind both promoters, but TAp73 transcription processes abrogate Nrf-2 binding. Methylation-induced silencing in cancerous tissues affects TAp73 expression to a larger extent as P1 contains three CpG islands while P2 harbors one. Consequently, enriched Nrf-2 binding at the P2 promoter activates abundant ΔNp73 transcription. Alternative splicing of pre-mRNA transcribed from the P1 promoter gives rise to DNp73 splice isoforms. Deregulation of factors that control p73 splicing is an important, however, largely unexplored area of research. Castillo et al. 161 showed that epidermal growth factor receptor is activated through a constitutive autocrine loop involving amphiregulin overexpression in cancer cells. Activated epidermal growth factor receptor induces JNK1-dependent phosphorylation of the transcriptional repressor Elk1, which downregulates the mRNA of the splicing factor SLU7. Suppression of SLU7 expression causes p73 pre-mRNA alternative splicing and, consequently, upregulation of ΔEx2p73.
Another strategy to outweigh TAp73 function is overexpression of isoform-specific protein-binding partners that selectively enhance the activity of amino-truncated p73 isoforms. The C35 protein has an important role in cancer progression and metastasis. It solely binds ΔNp73, but not TAp73, through interaction with the first unique 13 amino acids at the Nterminus. 162 The C35-ΔNp73 complex activates AKT signaling and expression of nuclear factor-κB (NFκB). Remarkably, C35-ΔNp73dependent NFκB nuclear activity was greatly enhanced in the presence of genotoxic drugs and conferred chemoresistance. C35 and ΔNp73 colocalize at peri-nuclear region, suggesting a transcriptional-independent mechanism of NFκB and AKT activation. 185, 186 EGCG (epigallocatechin-3-gallate ) Upregulation of TAp73 expression [187] [188] [189] Red wine polyphenol Upregulation of TAp73 expression 190 Arsenic trioxide Upregulation of TAp73 expression 191, 192 T-oligo Oligonucleotides homologous to the 3′-telomere overhang; upregulation of TAp73 expression 167, 193, 194 Propranolol Nonselective β-adrenergic receptor antagonist; upregulation of TAp73 expression 195 Melphalan Upregulation of TAp73 expression 196 Sodium butyrate Histone deacetylase inhibitor; upregulation of TAp73 expression Inhibits ΔEx2/3p73 mRNA 20, 168 p73 variants in cancer progression D Engelmann et al
CONCLUDING REMARKS
Tissue-specific and cell context-dependent expression of the multiple TA and DN isoforms of p73 in conjunction with the complex regulatome that governs their transcription, stability, subcellular localization and transactivation efficiency constitutes a comprehensive regulatory network responsive to a large variety of stimuli. Its deregulation during cancer progression causes inhibition of the TAp73 tumor-suppressor function and fosters novel oncogenic activities of DNp73 allowing the emergence of drug resistance, cancer metabolism, induction of EMT and metastasis. These insights draw immediate attention to individual or combined network components as therapeutic targets to combat metastatic cancer (Table 1) . Restoring the TAp73 tumor-suppressor function appears to be one possible strategy for putting brakes on cancer progression. In this regard, numerous studies led to the identification of compounds able to inhibit or displace negative regulators of TAp73. For example, the mTOR inhibitor rapamycin activates TAp73-mediated gene expression and sensitizes aggressive cancer cells to CDDP treatment. 58, 163 Pharmacological stimulation of AMP-activated protein kinase leads to accumulation of TAp73 in the nucleus via direct phosphorylation and causes apoptosis, however, only in the presence of p53. 164 Smallmolecule inhibitors of phosphatidylinositol 3′-kinase, AKT or prodigiosin disrupt the inhibitory effect of mutant p53 on TAp73. 165, 166 T-oligos trigger inherent telomere-based DNAdamage responses and engage TAp73 in p53-deficient melanoma cells. 167 Not to forget is, however, that DNp73 confers GOF uncoupled from any TA-dependent antagonism, 2-4 which probably relies on a hitherto unknown target gene repertoire. This would mean that reactivation of TAp73 alone is insufficient for anti-metastatic treatment. In this case, DNp73 isoform-specific inhibitors such as ASO116 20,168 might be a better choice. In addition, targeting factors that selectively promote accumulation or activity of DNp73 isoforms may help to set novel patienttailored anti-metastatic therapies.
